about
Redox control of microglial function: molecular mechanisms and functional significanceModulation of proteostasis by transcription factor NRF2 and impact in neurodegenerative diseasesHeme oxygenase-1 induction modulates microsomal prostaglandin E synthase-1 expression and prostaglandin E(2) production in osteoarthritic chondrocytes.The PTEN/NRF2 axis promotes human carcinogenesisDiscovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's diseaseTranscription factor NRF2 controls the fate of neural stem cells in the subgranular zone of the hippocampus.WNT-3A regulates an Axin1/NRF2 complex that regulates antioxidant metabolism in hepatocytes.Dysfunction of the PI3K-Akt-GSK-3 pathway is a common feature in cell culture and in vivo models of prion disease.Nuclear import and export signals control the subcellular localization of Nurr1 protein in response to oxidative stress.SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner.Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson's disease.The muscarinic M1 receptor activates Nrf2 through a signaling cascade that involves protein kinase C and inhibition of GSK-3beta: connecting neurotransmission with neuroprotection.Transcription factor NFE2L2/NRF2 is a regulator of macroautophagy genes.Signaling through the leukocyte integrin LFA-1 in T cells induces a transient activation of Rac-1 that is regulated by Vav and PI3K/Akt-1.GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress.Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil.Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism.Transcription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach.Deficiency in the transcription factor NRF2 worsens inflammatory parameters in a mouse model with combined tauopathy and amyloidopathy.Regulation of Cu/Zn-Superoxide Dismutase Expression via the Phosphatidylinositol 3 Kinase/Akt Pathway and Nuclear Factor- BA role for APP in Wnt signalling links synapse loss with β-amyloid productionTranscription factor NFE2L2/NRF2 modulates chaperone-mediated autophagy through the regulation of LAMP2ATherapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
P50
Q27000279-F1BE3420-4F52-4AD7-9CF4-906C8A0D270EQ29247921-FF802CC0-A335-4722-9AD6-3CCDDD5491A4Q33442445-816B19F3-FF1A-4278-B4B6-1BE5E272FC58Q34579435-092DA888-D182-4488-9B64-9DA259D72DF9Q36329594-53148A76-3B5D-45D7-A782-D2C8AFDCE53BQ38698838-1CE4C743-50B9-445F-8FE2-3BBA6D2667DDQ38945976-ED82E5A7-6523-423A-B1CC-3E3D7BB71A1EQ39143238-50C55BEF-BBB8-4C59-B480-48222C268638Q39217465-B67460AB-C986-4A87-9A95-4D054EBB9A97Q39606140-40A9393C-DDC3-4318-8174-66C4FBFA238DQ39775786-0032279B-938A-4651-8032-0028A967052FQ39832626-A2E5D3AD-0010-40BB-8DDF-C20ABA014AF6Q41575678-3AC43101-87E7-4985-81E4-BDDDC8CF8CECQ42457125-698F43B1-AD9C-4261-9F75-F9D4C0765E9BQ46898715-9FF3603F-CF1B-49B0-AA73-3684BA01836DQ47620637-B8473A3C-2A5D-49D4-B119-CD587497DBB6Q50547983-63747924-BBAD-43F3-97C8-A8CD597A581DQ52673272-40D9292B-8F73-4890-9947-33ACDF2EBFD0Q55715569-C98976F5-4C5B-4C27-9A48-E39F1E200794Q58436351-2DD40396-A5AD-4D9A-9166-FF8D6C3BA3E2Q58714162-B42FA0AA-639B-443E-B2D4-081E0E4FC838Q61843146-505891B5-0EC6-4300-8734-C569E2A411E3Q90893987-7AFEE2B8-ED0A-41B4-9FF6-661275B824A4
P50
description
researcher
@en
wetenschapper
@nl
name
Ana I Rojo
@en
Ana I Rojo
@nl
type
label
Ana I Rojo
@en
Ana I Rojo
@nl
prefLabel
Ana I Rojo
@en
Ana I Rojo
@nl
P106
P31
P496
0000-0002-0312-5867